World Health Organization Includes the Cardiovascular Polypill in Its List of Essential Medicines After a Groundbreaking Study Led by the President of Mount Sinai Heart

title

The cardiovascular polypill, developed by the Spanish National Centre for Cardiovascular Research (CNIC) and the pharmaceutical company Ferrer, has been included by the World Health Organization (WHO) in its List of Essential Medicines.

 Those are findings from the SECURE trial led by Valentin Fuster, MD, PhD, President of Mount Sinai Heart, Physician-in-Chief of The Mount Sinai Hospital, and General Director of CNIC. The groundbreaking results were published in August 2022 in The New England Journal of Medicine

Learn More